Anupam Dutta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anupam Dutta has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Papori Gogoi
Department of Medicine, Assam Medical College and Hospital, Dibrugarh, India
3 shared publicationsAngshuman Boruah
Department of General Medicine, Assam Medical College and Hospital, Dibrugarh, IND
2 shared publicationsAnkita Banik
Department of Medicine, Assam Medical College and Hospital, Dibrugarh, IND
2 shared publications- Annemari Käräjämäki
Department of Primary Health Care, Vaasa Central Hospital, Vaasa, Finland
2 shared publications - Banshi Saboo
Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India
2 shared publications - Bhabani Shankar Dhal
Department of Medicine, Assam Medical College , Dibrugarh , India
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in Cureus
- Vol. 18 (7)
Prevalence of Glutamic Acid Decarboxylase (GAD) Antibody Positivity in Young-Onset Diabetes: A Retrospective Study From Northeast India
Background: Latent autoimmune diabetes in adults (LADA) is a distinct form of diabetes characterized by autoimmune β-cell destruction with a slower progression compared to classical type 1 diabetes. It is frequently misclassified as type 2 diabetes, particularly in younger individuals, leading to suboptimal management. The presence of anti-glutamic acid decarboxylase (GAD) antibodies is a key diagnostic marker for LADA. However, data on the prevalence and distribution of GAD antibodies among young-onset diabetes patients in Northeast India are limited. Methods: This retrospective cross-sectional study was conducted at the Multidisciplinary Research Unit of a tertiary care center in Northeast India using archived serum samples from the Indian Council of Medical Research (ICMR)-funded PHENOEINDY-2 (Phenotyping North East Indian Young Type 2 Diabetes) cohort study (2017-2021). A total of 149 individuals diagnosed with diabetes before 40 years of age were included based on the availability of adequate stored serum samples. Serum anti-GAD antibody levels were measured using a standardized enzyme-linked immunosorbent assay (ELISA). Participants were categorized as GAD-negative (<5 U/mL) or GAD-positive (≥5 U/mL), the latter considered suggestive of an autoimmune diabetes phenotype. Descriptive analyses were performed to determine the prevalence and distribution of GAD antibody levels. Results: The overall mean GAD antibody level was 3.17 U/mL, with a median of 1.07 U/mL and a wide range (0.26-109.15 U/mL), demonstrating a markedly right-skewed distribution (skewness 7.52; kurtosis 63.29). Fourteen patients (9.4%) were classified as GAD-positive, indicating a probable diagnosis of LADA. The GAD-negative group (n=135) showed a tightly clustered distribution with low variability (mean 0.95 U/mL; SD 0.54 U/mL), consistent with non-autoimmune diabetes. In contrast, the GAD-positive group exhibited substantial heterogeneity (mean 24.58 U/mL; SD 29.67 U/mL), with several individuals demonstrating markedly elevated antibody levels exceeding 70-100 U/mL. Visual analyses confirmed a clear separation between the two groups, with compact clustering in the GAD-negative cohort and a wide dispersion in the GAD-positive subgroup. Conclusion: Approximately 1 in 10 young-onset diabetes patients in this cohort demonstrated GAD positivity, suggesting that autoimmune diabetes represents an important subset of young-onset diabetes in Northeast India. These findings provide preliminary epidemiological evidence on the prevalence of GAD positivity in this population and support the need for larger prospective studies incorporating detailed clinical phenotyping, metabolic follow-up, and evaluation of the clinical utility of GAD antibody testing to improve diagnostic classification and patient management.
- 1 July 2026
- Published by Springer Nature in Cureus
- Vol. 18 (7)
Open AccessPrevalence of Glutamic Acid Decarboxylase (GAD) Antibody Positivity in Young-Onset Diabetes: A Retrospective Study From Northeast India
Background: Latent autoimmune diabetes in adults (LADA) is a distinct form of diabetes characterized by autoimmune β-cell destruction with a slower progression compared to classical type 1 diabetes. It is frequently misclassified as type 2 diabetes, particularly in younger individuals, leading to suboptimal management. The presence of anti-glutamic acid decarboxylase (GAD) antibodies is a key diagnostic marker for LADA. However, data on the prevalence and distribution of GAD antibodies among young-onset diabetes patients in Northeast India are limited. Methods: This retrospective cross-sectional study was conducted at the Multidisciplinary Research Unit of a tertiary care center in Northeast India using archived serum samples from the Indian Council of Medical Research (ICMR)-funded PHENOEINDY-2 (Phenotyping North East Indian Young Type 2 Diabetes) cohort study (2017-2021). A total of 149 individuals diagnosed with diabetes before 40 years of age were included based on the availability of adequate stored serum samples. Serum anti-GAD antibody levels were measured using a standardized enzyme-linked immunosorbent assay (ELISA). Participants were categorized as GAD-negative (<5 U/mL) or GAD-positive (≥5 U/mL), the latter considered suggestive of an autoimmune diabetes phenotype. Descriptive analyses were performed to determine the prevalence and distribution of GAD antibody levels. Results: The overall mean GAD antibody level was 3.17 U/mL, with a median of 1.07 U/mL and a wide range (0.26-109.15 U/mL), demonstrating a markedly right-skewed distribution (skewness 7.52; kurtosis 63.29). Fourteen patients (9.4%) were classified as GAD-positive, indicating a probable diagnosis of LADA. The GAD-negative group (n=135) showed a tightly clustered distribution with low variability (mean 0.95 U/mL; SD 0.54 U/mL), consistent with non-autoimmune diabetes. In contrast, the GAD-positive group exhibited substantial heterogeneity (mean 24.58 U/mL; SD 29.67 U/mL), with several individuals demonstrating markedly elevated antibody levels exceeding 70-100 U/mL. Visual analyses confirmed a clear separation between the two groups, with compact clustering in the GAD-negative cohort and a wide dispersion in the GAD-positive subgroup. Conclusion: Approximately 1 in 10 young-onset diabetes patients in this cohort demonstrated GAD positivity, suggesting that autoimmune diabetes represents an important subset of young-onset diabetes in Northeast India. These findings provide preliminary epidemiological evidence on the prevalence of GAD positivity in this population and support the need for larger prospective studies incorporating detailed clinical phenotyping, metabolic follow-up, and evaluation of the clinical utility of GAD antibody testing to improve diagnostic classification and patient management.
- Open Access
- 25 March 2026
- Published by Scientific Scholar in Academic Bulletin of Mental Health
- Vol. 4, 73-76
Psychiatric Adverse Reaction to Triple Therapy for Helicobacter Pylori : A Case of Reversible Clarithromycin-Induced Psychosis
Standard Helicobacter pylori ( H. pylori ) eradication regimens, commonly consisting of a proton pump inhibitor (PPI) combined with clarithromycin and amoxicillin, are widely regarded as safe and effective. However, clarithromycin has been rarely implicated in neuropsychiatric side effects, including acute psychosis. The onset of such adverse events can pose diagnostic dilemmas, particularly in patients without any pre-existing psychiatric history. We present a case of clarithromycin-associated transient psychosis in an otherwise healthy adult male, occurring shortly after initiation of triple therapy for H. pylori . A 35-year-old man presented with upper abdominal discomfort and was diagnosed with H. pylori -induced gastritis via upper gastrointestinal endoscopy and biopsy. He was started on standard triple therapy: clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and pantoprazole 40 mg twice daily. Within 36 hours of starting treatment, he developed acute-onset behavioral disturbances, including paranoia, auditory hallucinations, disorganized speech, and psychomotor agitation. There was no history of psychiatric illness, substance abuse, or concurrent medication use. Laboratory evaluations, including metabolic panels, thyroid function, liver and renal parameters, were unremarkable. Computed tomography (CT) brain imaging was normal, and no signs of systemic infection were present. A provisional diagnosis of drug-induced psychosis was made. The eradication therapy was immediately discontinued, and the patient received supportive care with low-dose risperidone. Complete resolution of symptoms occurred within 48 hours of withdrawal, and the patient remained asymptomatic at 4-week follow-up. Clarithromycin is known to penetrate the blood-brain barrier and may exert neurotoxic effects through Gamma-Aminobutyric Acid (GABA) ergic modulation or proinflammatory cytokine release. Although rare, acute psychosis associated with clarithromycin has been reported in several case studies, typically with a rapid onset and full recovery following drug discontinuation. Awareness of this potential adverse effect is crucial to prevent misdiagnosis and unnecessary psychiatric treatment. Clinicians should maintain a high index of suspicion for antibiotic-induced neuropsychiatric events, especially with macrolides like clarithromycin. Early recognition and prompt withdrawal can lead to rapid recovery without long-term sequelae.
- 25 March 2026
- Published by Scientific Scholar in Academic Bulletin of Mental Health
- Vol. 4, 73-76
Open AccessPsychiatric Adverse Reaction to Triple Therapy for Helicobacter Pylori : A Case of Reversible Clarithromycin-Induced Psychosis
Standard Helicobacter pylori ( H. pylori ) eradication regimens, commonly consisting of a proton pump inhibitor (PPI) combined with clarithromycin and amoxicillin, are widely regarded as safe and effective. However, clarithromycin has been rarely implicated in neuropsychiatric side effects, including acute psychosis. The onset of such adverse events can pose diagnostic dilemmas, particularly in patients without any pre-existing psychiatric history. We present a case of clarithromycin-associated transient psychosis in an otherwise healthy adult male, occurring shortly after initiation of triple therapy for H. pylori . A 35-year-old man presented with upper abdominal discomfort and was diagnosed with H. pylori -induced gastritis via upper gastrointestinal endoscopy and biopsy. He was started on standard triple therapy: clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and pantoprazole 40 mg twice daily. Within 36 hours of starting treatment, he developed acute-onset behavioral disturbances, including paranoia, auditory hallucinations, disorganized speech, and psychomotor agitation. There was no history of psychiatric illness, substance abuse, or concurrent medication use. Laboratory evaluations, including metabolic panels, thyroid function, liver and renal parameters, were unremarkable. Computed tomography (CT) brain imaging was normal, and no signs of systemic infection were present. A provisional diagnosis of drug-induced psychosis was made. The eradication therapy was immediately discontinued, and the patient received supportive care with low-dose risperidone. Complete resolution of symptoms occurred within 48 hours of withdrawal, and the patient remained asymptomatic at 4-week follow-up. Clarithromycin is known to penetrate the blood-brain barrier and may exert neurotoxic effects through Gamma-Aminobutyric Acid (GABA) ergic modulation or proinflammatory cytokine release. Although rare, acute psychosis associated with clarithromycin has been reported in several case studies, typically with a rapid onset and full recovery following drug discontinuation. Awareness of this potential adverse effect is crucial to prevent misdiagnosis and unnecessary psychiatric treatment. Clinicians should maintain a high index of suspicion for antibiotic-induced neuropsychiatric events, especially with macrolides like clarithromycin. Early recognition and prompt withdrawal can lead to rapid recovery without long-term sequelae.
- 9 March 2026
- Published by Wiley in Haemophilia
- Vol. 32 (4) , 905-913
Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata
Background: Haemophilia care varies across economic settings, influencing diagnosis, treatment and outcomes. The World Bleeding Disorders Registry (WBDR) enables standardized, patient‐level global benchmarking. We present the first multicentre analysis of Indian persons with haemophilia (PwH) in the WBDR, enabling robust benchmarking against regional and income‐stratified global cohorts. Methods: This cross‐sectional study analysed de‐identified WBDR data from six haemophilia treatment centres in India across geographic areas. Standardized demographic, clinical, and treatment indicators were benchmarked against South‐East Asia (SEA), income‐stratified global WBDR cohorts, and World Federation of Hemophilia Annual Global Survey (WFH AGS) 2023 data, focusing on diagnosis, severity, treatment, functional status, inhibitor status and employment. Results: Among 1,780 PwH (86% haemophilia A), 77% had severe disease. Median age was 20 years (IQR 11–31), significantly younger than global WBDR and AGS cohorts ( p < 0.001). Median age at diagnosis for severe haemophilia was 60 months (IQR 12180), markedly later than in upper‐middle‐ and high‐income countries ( p < 10 − 1 5 ). Only 7% of severe PwH received prophylaxis compared with >60% in high‐income settings, higher ABR (median 6 vs 01) and greater target‐joint prevalence (31% vs 9%; p < 0.001). Among adults, 62% were employed, comparable to other lower‐middle‐income countries. Inhibitor surveillance was limited: 2% of severe PwH were tested in the prior 12 months, while lifetime inhibitor prevalence was 14%, similar to regional LMIC cohorts. Conclusions: Indian WBDR data underscore the value of registry participation for meaningful benchmarking of haemophilia care, highlighting progress in diagnosis and employment outcomes alongside clear opportunities to expand treatment coverage and improve clinical outcomes.
- 9 March 2026
- Published by Wiley in Haemophilia
- Vol. 32 (4) , 905-913
Haemophilia Care in India: A Multicentre Cross‐Sectional Analysis From the World Bleeding Disorders Registry Benchmarking Across Global Gross National Income Strata
Background: Haemophilia care varies across economic settings, influencing diagnosis, treatment and outcomes. The World Bleeding Disorders Registry (WBDR) enables standardized, patient‐level global benchmarking. We present the first multicentre analysis of Indian persons with haemophilia (PwH) in the WBDR, enabling robust benchmarking against regional and income‐stratified global cohorts. Methods: This cross‐sectional study analysed de‐identified WBDR data from six haemophilia treatment centres in India across geographic areas. Standardized demographic, clinical, and treatment indicators were benchmarked against South‐East Asia (SEA), income‐stratified global WBDR cohorts, and World Federation of Hemophilia Annual Global Survey (WFH AGS) 2023 data, focusing on diagnosis, severity, treatment, functional status, inhibitor status and employment. Results: Among 1,780 PwH (86% haemophilia A), 77% had severe disease. Median age was 20 years (IQR 11–31), significantly younger than global WBDR and AGS cohorts ( p < 0.001). Median age at diagnosis for severe haemophilia was 60 months (IQR 12180), markedly later than in upper‐middle‐ and high‐income countries ( p < 10 − 1 5 ). Only 7% of severe PwH received prophylaxis compared with >60% in high‐income settings, higher ABR (median 6 vs 01) and greater target‐joint prevalence (31% vs 9%; p < 0.001). Among adults, 62% were employed, comparable to other lower‐middle‐income countries. Inhibitor surveillance was limited: 2% of severe PwH were tested in the prior 12 months, while lifetime inhibitor prevalence was 14%, similar to regional LMIC cohorts. Conclusions: Indian WBDR data underscore the value of registry participation for meaningful benchmarking of haemophilia care, highlighting progress in diagnosis and employment outcomes alongside clear opportunities to expand treatment coverage and improve clinical outcomes.
- Open Access
- 15 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Compound Heterozygous Hemoglobin E-Beta (HbE-β)-Thalassemia Presenting With Chipmunk or Rodent Facies, and a Severe Thalassemia Major Phenotype
Hemoglobin E-beta (HbE-β)-thalassemia is a common compound hemoglobinopathy in South and Southeast Asia and is marked by considerable clinical heterogeneity, ranging from mild anemia to a severe, transfusion-dependent condition resembling β-thalassemia major (β-TM). The severity of disease is largely determined by the nature of the associated β-thalassemia mutation, modifiers of fetal hemoglobin, and access to early diagnosis and regular treatment. Severe skeletal deformities are now uncommon in the era of structured transfusion programs, but continue to be encountered in regions with delayed diagnosis and inadequate care. We report a 20-year-old female from Northeast India who presented with progressive facial disfigurement, dental malocclusion, growth failure, and delayed puberty. She had a history of long-standing anemia treated intermittently with blood transfusions and no prior iron chelation. Clinical examination revealed classical craniofacial abnormalities, including frontal bossing, prominent malar eminences, and marked maxillary hypertrophy, producing the characteristic chipmunk or rodent facies. Radiological evaluation of the skull demonstrated widening of the diploë with a hair-on-end appearance, consistent with chronic marrow hyperplasia and extramedullary hematopoiesis. Molecular analysis confirmed compound heterozygosity for HbE (HBB:c.79G>A) and a severe β-thalassemia splice-site mutation, IVS-I-5 (G>C) (HBB:c.92+5G>C). Despite the HbE-β-thalassemia genotype, the patient exhibited a phenotype indistinguishable from classical β-TM, including severe anemia, stunted growth, primary amenorrhea, and advanced skeletal deformity. This case highlights the severe end of the HbE-β-thalassemia spectrum and underscores that compound heterozygous states may present with a β-TM-like phenotype. Early diagnosis, regular transfusion-chelation therapy, and genotype-phenotype-guided management are essential to prevent irreversible skeletal and endocrine complications.
- 15 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessCompound Heterozygous Hemoglobin E-Beta (HbE-β)-Thalassemia Presenting With Chipmunk or Rodent Facies, and a Severe Thalassemia Major Phenotype
Hemoglobin E-beta (HbE-β)-thalassemia is a common compound hemoglobinopathy in South and Southeast Asia and is marked by considerable clinical heterogeneity, ranging from mild anemia to a severe, transfusion-dependent condition resembling β-thalassemia major (β-TM). The severity of disease is largely determined by the nature of the associated β-thalassemia mutation, modifiers of fetal hemoglobin, and access to early diagnosis and regular treatment. Severe skeletal deformities are now uncommon in the era of structured transfusion programs, but continue to be encountered in regions with delayed diagnosis and inadequate care. We report a 20-year-old female from Northeast India who presented with progressive facial disfigurement, dental malocclusion, growth failure, and delayed puberty. She had a history of long-standing anemia treated intermittently with blood transfusions and no prior iron chelation. Clinical examination revealed classical craniofacial abnormalities, including frontal bossing, prominent malar eminences, and marked maxillary hypertrophy, producing the characteristic chipmunk or rodent facies. Radiological evaluation of the skull demonstrated widening of the diploë with a hair-on-end appearance, consistent with chronic marrow hyperplasia and extramedullary hematopoiesis. Molecular analysis confirmed compound heterozygosity for HbE (HBB:c.79G>A) and a severe β-thalassemia splice-site mutation, IVS-I-5 (G>C) (HBB:c.92+5G>C). Despite the HbE-β-thalassemia genotype, the patient exhibited a phenotype indistinguishable from classical β-TM, including severe anemia, stunted growth, primary amenorrhea, and advanced skeletal deformity. This case highlights the severe end of the HbE-β-thalassemia spectrum and underscores that compound heterozygous states may present with a β-TM-like phenotype. Early diagnosis, regular transfusion-chelation therapy, and genotype-phenotype-guided management are essential to prevent irreversible skeletal and endocrine complications.
- Open Access
- 13 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Twelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A
Background: Hemophilia A (HA) management remains challenging in northeastern India due to limited access to specialized care. Emicizumab, a bispecific monoclonal antibody, offers prophylactic benefits for patients with or without factor VIII (FVIII) inhibitors. Objectives: The study aimed to assess the long-term effectiveness, safety, and patient-reported outcomes of emicizumab prophylaxis in people with HA with or without inhibitors. Design: This 12-month follow-up from a noninterventional, real-world observational study builds on previously published 6-month data and was conducted at the Department of General Medicine, Assam Medical College and Hospital, India. Methods: Forty pediatric patients with moderate-to-severe HA, including those with inhibitors, receiving emicizumab prophylaxis were followed at a treatment center. The outcomes assessed at baseline, 6 months, and 12 months included annualized bleeding rate (ABR), Hemophilia Joint Health Score (HJHS), Functional Independence Score in Hemophilia (FISH), European QoL-5 dimensional-5 level (EQ-5D-5L) score and visual analog scale (VAS). Subgroup analyses explored age- and inhibitor-status based differences. Data were analyzed using appropriate statistical tests to compare outcomes across time points and subgroups. Results: The mean ABR reduced significantly from 11.48 at baseline to 0.05 at 12 months ( p < 0.001), with all patients showing improvement. Joint and target joint bleeds were eliminated. HJHS improved from mean 12.0 ± 5.23 to 4.6 ± 3.13, and FISH increased from 27.5 ± 2.11 to 30.6 ± 1.39 (both p < 0.001). EQ-5D-5L index and VAS scores also showed significant gains. Notably, age-related disparities in ABR, evident with FVIII therapy, were no longer apparent after emicizumab therapy, highlighting its uniform effectiveness from early childhood. Conclusion: This 12-month follow-up study from northeastern India confirms the sustained efficacy and safety of emicizumab in reducing bleeds and improving outcomes in children with HA. The findings underscore its value in underserved settings, supporting broader implementation in similar healthcare environments.
- 13 February 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessTwelve-month follow-up of a real-world, noninterventional study evaluating the impact of emicizumab on bleeding episodes, joint health, and quality of life in people with hemophilia A
Background: Hemophilia A (HA) management remains challenging in northeastern India due to limited access to specialized care. Emicizumab, a bispecific monoclonal antibody, offers prophylactic benefits for patients with or without factor VIII (FVIII) inhibitors. Objectives: The study aimed to assess the long-term effectiveness, safety, and patient-reported outcomes of emicizumab prophylaxis in people with HA with or without inhibitors. Design: This 12-month follow-up from a noninterventional, real-world observational study builds on previously published 6-month data and was conducted at the Department of General Medicine, Assam Medical College and Hospital, India. Methods: Forty pediatric patients with moderate-to-severe HA, including those with inhibitors, receiving emicizumab prophylaxis were followed at a treatment center. The outcomes assessed at baseline, 6 months, and 12 months included annualized bleeding rate (ABR), Hemophilia Joint Health Score (HJHS), Functional Independence Score in Hemophilia (FISH), European QoL-5 dimensional-5 level (EQ-5D-5L) score and visual analog scale (VAS). Subgroup analyses explored age- and inhibitor-status based differences. Data were analyzed using appropriate statistical tests to compare outcomes across time points and subgroups. Results: The mean ABR reduced significantly from 11.48 at baseline to 0.05 at 12 months ( p < 0.001), with all patients showing improvement. Joint and target joint bleeds were eliminated. HJHS improved from mean 12.0 ± 5.23 to 4.6 ± 3.13, and FISH increased from 27.5 ± 2.11 to 30.6 ± 1.39 (both p < 0.001). EQ-5D-5L index and VAS scores also showed significant gains. Notably, age-related disparities in ABR, evident with FVIII therapy, were no longer apparent after emicizumab therapy, highlighting its uniform effectiveness from early childhood. Conclusion: This 12-month follow-up study from northeastern India confirms the sustained efficacy and safety of emicizumab in reducing bleeds and improving outcomes in children with HA. The findings underscore its value in underserved settings, supporting broader implementation in similar healthcare environments.
- Open Access
- 30 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Unmasking Wiskott–Aldrich Syndrome in Adulthood in a Case of Long-Standing Bleeding, Infections, and Steroid-Induced Morbidity
Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by the classic triad of microthrombocytopenia, recurrent infections, and eczema, with most cases diagnosed during infancy or early childhood. Adult presentation is uncommon and often leads to diagnostic delay or misdiagnosis. We report the case of a 28-year-old male who presented with multiple episodes of bleeding, petechiae, recurrent skin and respiratory infections, and chronic eczematous lesions. Over several years, he underwent repeated hospitalizations and was treated for immune thrombocytopenia (ITP) with prolonged courses of oral corticosteroids, resulting in features of iatrogenic Cushing’s syndrome, including moon facies and skin thinning. Despite steroid therapy, his symptoms worsened, and he continued to have intermittent respiratory tract infections, urinary tract infections, and recurrent skin ulcers. The patient’s family history revealed consanguinity and recurrent infections among female relatives, including his mother and maternal aunt, raising suspicion for an inherited immunodeficiency. On examination, he had diffuse eczematous lesions over the hands and feet, petechiae, and Cushingoid features. Laboratory investigations showed persistent thrombocytopenia with a low mean platelet volume, elevated inflammatory markers, and evidence of immune dysregulation. Given the constellation of symptoms, a primary immunodeficiency was suspected, prompting genetic evaluation. Whole-exome sequencing identified a hemizygous pathogenic nonsense variant in the WAS gene: NM_000377.3; chrX:48688689; c.961C>T; p.Arg321* in exon 10, confirming the diagnosis of WAS. This variant is predicted to result in the premature truncation of the WAS protein and is consistent with a classical WAS phenotype. This case highlights the challenges in diagnosing WAS in adulthood, especially when initial symptoms mimic more common hematological conditions such as ITP. Early recognition of syndromic features and consideration of inherited immunodeficiencies in persistent thrombocytopenia with eczema can prevent prolonged steroid exposure and facilitate timely, appropriate management.
- 30 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Open AccessUnmasking Wiskott–Aldrich Syndrome in Adulthood in a Case of Long-Standing Bleeding, Infections, and Steroid-Induced Morbidity
Wiskott-Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by the classic triad of microthrombocytopenia, recurrent infections, and eczema, with most cases diagnosed during infancy or early childhood. Adult presentation is uncommon and often leads to diagnostic delay or misdiagnosis. We report the case of a 28-year-old male who presented with multiple episodes of bleeding, petechiae, recurrent skin and respiratory infections, and chronic eczematous lesions. Over several years, he underwent repeated hospitalizations and was treated for immune thrombocytopenia (ITP) with prolonged courses of oral corticosteroids, resulting in features of iatrogenic Cushing’s syndrome, including moon facies and skin thinning. Despite steroid therapy, his symptoms worsened, and he continued to have intermittent respiratory tract infections, urinary tract infections, and recurrent skin ulcers. The patient’s family history revealed consanguinity and recurrent infections among female relatives, including his mother and maternal aunt, raising suspicion for an inherited immunodeficiency. On examination, he had diffuse eczematous lesions over the hands and feet, petechiae, and Cushingoid features. Laboratory investigations showed persistent thrombocytopenia with a low mean platelet volume, elevated inflammatory markers, and evidence of immune dysregulation. Given the constellation of symptoms, a primary immunodeficiency was suspected, prompting genetic evaluation. Whole-exome sequencing identified a hemizygous pathogenic nonsense variant in the WAS gene: NM_000377.3; chrX:48688689; c.961C>T; p.Arg321* in exon 10, confirming the diagnosis of WAS. This variant is predicted to result in the premature truncation of the WAS protein and is consistent with a classical WAS phenotype. This case highlights the challenges in diagnosing WAS in adulthood, especially when initial symptoms mimic more common hematological conditions such as ITP. Early recognition of syndromic features and consideration of inherited immunodeficiencies in persistent thrombocytopenia with eczema can prevent prolonged steroid exposure and facilitate timely, appropriate management.
- Open Access
- 9 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Measuring Adipocytokines in Young Patients With Type 2 Diabetes Presenting to a Tertiary Care Centre in Upper Assam, India
Background Type 2 diabetes mellitus (T2DM) in lean and young adults is emerging as a distinct phenotype in South Asia, often dissociated from obesity-driven insulin resistance. This study evaluated adipocytokines (adiponectin and leptin) and inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)) in young T2DM and non-diabetic individuals across body mass index (BMI) categories to elucidate underlying metabolic and inflammatory profiles. Methods A hospital-based case-control analysis was conducted among 176 individuals (age and sex matched, 83 diabetics, 93 non-diabetics) aged 18-45 years (105 females, 71 males), drawn from the PHENOEINDY-2 cohort at Assam Medical College and Hospital, Dibrugarh. Participants were stratified into four BMI groups: underweight (30 kg/m²). Serum adiponectin, leptin, IL-6, and high-sensitivity CRP (hs-CRP) were measured using enzyme-linked immunosorbent assay (ELISA)-based assays. Statistical comparisons employed t-tests, ANOVA, and regression modeling, adjusting for age and socioeconomic factors. Results Among diabetics, mean adiponectin was highest in the underweight group (3.44 ± 2.56 µg/mL) and declined with increasing BMI, showing a significant negative correlation with BMI (r =-0.65, P = 0.079). Leptin demonstrated a strong positive correlation with BMI (r = 0.77, P = 0.024), increasing progressively from underweight (0.54 ± 0.66 ng/mL) to obese participants (0.80 ± 0.96 ng/mL). CRP levels were markedly elevated in underweight diabetics (8.15 ± 11.9 mg/L) versus non-diabetics (2.19 ± 1.75 mg/L, P = 0.075), suggesting low-grade inflammation even in non-obese individuals. A positive association between CRP and BMI (r = 0.67, P = 0.012) was observed overall. IL-6 levels peaked among normal-weight (102.36 ± 179.5 pg/mL) and overweight diabetics (118.72 ± 163.38 pg/mL), without significant correlation with BMI (r =-0.12, P = 0.777), indicating adiposity-independent inflammation. Logistic regression incorporating all biomarkers yielded a modest predictive accuracy of 33.3%, with CRP emerging as the most influential predictor of diabetes risk, followed by IL-6. Scatter plots confirmed negative trends for adiponectin and positive associations for leptin and CRP with BMI, while IL-6 remained BMI-independent. Interpretation Lean diabetics exhibited distinct biochemical features-higher adiponectin but elevated CRP and IL-6supporting inflammation and β-cell dysfunction as key drivers over insulin resistance. In contrast, obese diabetics demonstrated low adiponectin and high leptin, reflecting adiposity-linked metabolic stress. The elevated inflammatory markers among lean diabetics highlight non-adipose origins of inflammation, possibly from hepatic or immune pathways. Conclusions This study underscores heterogeneity in T2DM pathophysiology across BMI categories in Northeast India. Inflammation, rather than adiposity, may underlie dysglycemia among lean individuals, while adipokine imbalance predominates in obesity-associated diabetes. Integrating adiponectin, CRP, and IL-6 into risk assessment could refine screening for atypical or lean T2DM phenotypes. Future longitudinal and genetic studies are warranted to dissect the contribution of developmental and ethnic factors unique to this population.
- 9 December 2025
- Published by Springer Nature in Cureus
- Vol. 17 (12)
Open AccessMeasuring Adipocytokines in Young Patients With Type 2 Diabetes Presenting to a Tertiary Care Centre in Upper Assam, India
Background Type 2 diabetes mellitus (T2DM) in lean and young adults is emerging as a distinct phenotype in South Asia, often dissociated from obesity-driven insulin resistance. This study evaluated adipocytokines (adiponectin and leptin) and inflammatory markers (C-reactive protein (CRP) and interleukin-6 (IL-6)) in young T2DM and non-diabetic individuals across body mass index (BMI) categories to elucidate underlying metabolic and inflammatory profiles. Methods A hospital-based case-control analysis was conducted among 176 individuals (age and sex matched, 83 diabetics, 93 non-diabetics) aged 18-45 years (105 females, 71 males), drawn from the PHENOEINDY-2 cohort at Assam Medical College and Hospital, Dibrugarh. Participants were stratified into four BMI groups: underweight (30 kg/m²). Serum adiponectin, leptin, IL-6, and high-sensitivity CRP (hs-CRP) were measured using enzyme-linked immunosorbent assay (ELISA)-based assays. Statistical comparisons employed t-tests, ANOVA, and regression modeling, adjusting for age and socioeconomic factors. Results Among diabetics, mean adiponectin was highest in the underweight group (3.44 ± 2.56 µg/mL) and declined with increasing BMI, showing a significant negative correlation with BMI (r =-0.65, P = 0.079). Leptin demonstrated a strong positive correlation with BMI (r = 0.77, P = 0.024), increasing progressively from underweight (0.54 ± 0.66 ng/mL) to obese participants (0.80 ± 0.96 ng/mL). CRP levels were markedly elevated in underweight diabetics (8.15 ± 11.9 mg/L) versus non-diabetics (2.19 ± 1.75 mg/L, P = 0.075), suggesting low-grade inflammation even in non-obese individuals. A positive association between CRP and BMI (r = 0.67, P = 0.012) was observed overall. IL-6 levels peaked among normal-weight (102.36 ± 179.5 pg/mL) and overweight diabetics (118.72 ± 163.38 pg/mL), without significant correlation with BMI (r =-0.12, P = 0.777), indicating adiposity-independent inflammation. Logistic regression incorporating all biomarkers yielded a modest predictive accuracy of 33.3%, with CRP emerging as the most influential predictor of diabetes risk, followed by IL-6. Scatter plots confirmed negative trends for adiponectin and positive associations for leptin and CRP with BMI, while IL-6 remained BMI-independent. Interpretation Lean diabetics exhibited distinct biochemical features-higher adiponectin but elevated CRP and IL-6supporting inflammation and β-cell dysfunction as key drivers over insulin resistance. In contrast, obese diabetics demonstrated low adiponectin and high leptin, reflecting adiposity-linked metabolic stress. The elevated inflammatory markers among lean diabetics highlight non-adipose origins of inflammation, possibly from hepatic or immune pathways. Conclusions This study underscores heterogeneity in T2DM pathophysiology across BMI categories in Northeast India. Inflammation, rather than adiposity, may underlie dysglycemia among lean individuals, while adipokine imbalance predominates in obesity-associated diabetes. Integrating adiponectin, CRP, and IL-6 into risk assessment could refine screening for atypical or lean T2DM phenotypes. Future longitudinal and genetic studies are warranted to dissect the contribution of developmental and ethnic factors unique to this population.
- Open Access
- 8 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Castleman Disease in a Child: A Rare Cause of Persistent Cervical Lymphadenopathy
Castleman disease (CD) is a rare, heterogeneous group of lymphoproliferative disorders characterized by distinctive histopathological changes. It can present as unicentric (UCD), involving a single nodal region, or multicentric (MCD), with generalized lymphadenopathy and systemic inflammation. Due to its rarity and overlapping features with infections and malignancies, diagnosis is often delayed. We report the case of a 12-year-old female who presented with progressive, multiple left-sided cervical swellings since 2023, associated with intermittent low-grade fever, headache, and fatigue. Despite empirical treatments with antibiotics and anti-tubercular therapy, her symptoms persisted. Investigations revealed anemia with hemoglobin E trait, hepatomegaly, abdominal lymphadenopathy, and minimal ascites. Cervical lymph node biopsy confirmed Castleman disease of mixed hyaline vascular and plasma cell type. Additional workup showed Epstein-Barr virus positivity, elevated IgE (>3000 IU/mL), and high IgG levels. The patient received intravenous methylprednisolone, followed by three cycles of rituximab with partial reduction of lymphadenopathy. Subsequently, a modified radical neck dissection (Type III) was performed, yielding multiple enlarged lymph nodes, the largest measuring 8 × 4 × 2 cm. Histopathology confirmed the diagnosis, showing atretic germinal centers, hyalinisation, intrafollicular vascular proliferation, and plasma cell infiltrates. This case highlights the diagnostic challenges of Castleman disease in children, its overlap with common conditions like tuberculosis, and the importance of multidisciplinary evaluation and combined medical-surgical therapy for optimal outcomes.
- 8 November 2025
- Published by Springer Nature in Cureus
- Vol. 17 (11)
Open AccessCastleman Disease in a Child: A Rare Cause of Persistent Cervical Lymphadenopathy
Castleman disease (CD) is a rare, heterogeneous group of lymphoproliferative disorders characterized by distinctive histopathological changes. It can present as unicentric (UCD), involving a single nodal region, or multicentric (MCD), with generalized lymphadenopathy and systemic inflammation. Due to its rarity and overlapping features with infections and malignancies, diagnosis is often delayed. We report the case of a 12-year-old female who presented with progressive, multiple left-sided cervical swellings since 2023, associated with intermittent low-grade fever, headache, and fatigue. Despite empirical treatments with antibiotics and anti-tubercular therapy, her symptoms persisted. Investigations revealed anemia with hemoglobin E trait, hepatomegaly, abdominal lymphadenopathy, and minimal ascites. Cervical lymph node biopsy confirmed Castleman disease of mixed hyaline vascular and plasma cell type. Additional workup showed Epstein-Barr virus positivity, elevated IgE (>3000 IU/mL), and high IgG levels. The patient received intravenous methylprednisolone, followed by three cycles of rituximab with partial reduction of lymphadenopathy. Subsequently, a modified radical neck dissection (Type III) was performed, yielding multiple enlarged lymph nodes, the largest measuring 8 × 4 × 2 cm. Histopathology confirmed the diagnosis, showing atretic germinal centers, hyalinisation, intrafollicular vascular proliferation, and plasma cell infiltrates. This case highlights the diagnostic challenges of Castleman disease in children, its overlap with common conditions like tuberculosis, and the importance of multidisciplinary evaluation and combined medical-surgical therapy for optimal outcomes.
- Open Access
- 17 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9) , e92588
Silent Avascular Necrosis of the Femoral Head in Severe Hemophilia A: A Case Report
Avascular necrosis (AVN) of the femoral head is a rare but serious complication in patients with hemophilia. While hemarthroses commonly affect the knees, elbows, and ankles, hip involvement is less frequent and often overlooked, leading to delayed diagnosis, especially when presentation is silent. We report a case of a 32-year-old man with severe hemophilia A, diagnosed at age 11, who presented with progressive limp and right hip pain for six weeks. His treatment history revealed lifelong on-demand factor VIII replacement due to financial constraints, with multiple joint bleeds resulting in advanced hemophilic arthropathy. Despite a high Hemophilia Joint Health Score (HJHS) and a low Functional Independence Score in Hemophilia (FISH), he had never reported hip symptoms previously. Socioeconomic hardship, a lack of education, and complex family issues further hindered regular prophylaxis. Imaging with a computed tomography (CT) scan revealed avascular necrosis of the right femoral head. This case highlights the need for heightened awareness of silent AVN in persons with hemophilia, especially those on inadequate prophylaxis and with advanced joint disease. Routine hip screening should be a part of comprehensive musculoskeletal surveillance to detect early changes and enable timely intervention, ultimately preserving joint function and quality of life in resource-limited settings.
- 17 September 2025
- Published by Springer Nature in Cureus
- Vol. 17 (9) , e92588
Open AccessSilent Avascular Necrosis of the Femoral Head in Severe Hemophilia A: A Case Report
Avascular necrosis (AVN) of the femoral head is a rare but serious complication in patients with hemophilia. While hemarthroses commonly affect the knees, elbows, and ankles, hip involvement is less frequent and often overlooked, leading to delayed diagnosis, especially when presentation is silent. We report a case of a 32-year-old man with severe hemophilia A, diagnosed at age 11, who presented with progressive limp and right hip pain for six weeks. His treatment history revealed lifelong on-demand factor VIII replacement due to financial constraints, with multiple joint bleeds resulting in advanced hemophilic arthropathy. Despite a high Hemophilia Joint Health Score (HJHS) and a low Functional Independence Score in Hemophilia (FISH), he had never reported hip symptoms previously. Socioeconomic hardship, a lack of education, and complex family issues further hindered regular prophylaxis. Imaging with a computed tomography (CT) scan revealed avascular necrosis of the right femoral head. This case highlights the need for heightened awareness of silent AVN in persons with hemophilia, especially those on inadequate prophylaxis and with advanced joint disease. Routine hip screening should be a part of comprehensive musculoskeletal surveillance to detect early changes and enable timely intervention, ultimately preserving joint function and quality of life in resource-limited settings.
- Open Access
- 26 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8) , e91018
Ocular Manifestations of Sickle Cell Disease With an Emphasis on Retinal Involvement
Background This study aimed to evaluate the spectrum of ocular manifestations in sickle cell disease (SCD) patients, with a particular emphasis on retinal involvement, to improve early diagnosis and management strategies. Methodology A cross-sectional, observational study was conducted over one year at Assam Medical College and Hospital, Dibrugarh, recruiting 96 SCD patients aged 10 and above. Comprehensive ophthalmological evaluations included best-corrected visual acuity, slit-lamp biomicroscopy, direct/indirect ophthalmoscopy, spectral-domain optical coherence tomography (OCT), and, in selected cases, fundus fluorescein angiography. Sickle cell retinopathy (SCR) was graded using Goldberg’s classification. Results The mean age of the participants was 31.00 ± 13.89 years, with 52 (54.17%) males and 71 (76.04%) from the tea tribe community. Systemic features included pallor in 85 (88.54%) and generalized weakness in 83 (86.46%) participants. Visual acuity of 6/6 to 6/9 was found in 32 (33.33%) (right eye) and 33 (34.38%) (left eye) participants. Anterior segment involvement (corkscrew vessels) was noted in 50 (52.08%) participants, and posterior segment changes were noted in 51 (53.13%) participants. Non-proliferative SCR was present in 46 (47.92%) and proliferative SCR in 5 (5.21%) participants. OCT revealed vitreomacular traction, epiretinal membranes, and full-thickness macular holes. Patient age correlated with retinopathy severity (R² = 0.76, p < 0.01), and systemic severity correlated with retinopathy (R² = 0.94, p < 0.001). Conclusions SCD patients exhibit significant ocular manifestations, particularly retinal pathology, which correlates with age and systemic disease severity. Early and routine ophthalmologic screening is crucial for timely management and preventing vision loss.
- 26 August 2025
- Published by Springer Nature in Cureus
- Vol. 17 (8) , e91018
Open AccessOcular Manifestations of Sickle Cell Disease With an Emphasis on Retinal Involvement
Background This study aimed to evaluate the spectrum of ocular manifestations in sickle cell disease (SCD) patients, with a particular emphasis on retinal involvement, to improve early diagnosis and management strategies. Methodology A cross-sectional, observational study was conducted over one year at Assam Medical College and Hospital, Dibrugarh, recruiting 96 SCD patients aged 10 and above. Comprehensive ophthalmological evaluations included best-corrected visual acuity, slit-lamp biomicroscopy, direct/indirect ophthalmoscopy, spectral-domain optical coherence tomography (OCT), and, in selected cases, fundus fluorescein angiography. Sickle cell retinopathy (SCR) was graded using Goldberg’s classification. Results The mean age of the participants was 31.00 ± 13.89 years, with 52 (54.17%) males and 71 (76.04%) from the tea tribe community. Systemic features included pallor in 85 (88.54%) and generalized weakness in 83 (86.46%) participants. Visual acuity of 6/6 to 6/9 was found in 32 (33.33%) (right eye) and 33 (34.38%) (left eye) participants. Anterior segment involvement (corkscrew vessels) was noted in 50 (52.08%) participants, and posterior segment changes were noted in 51 (53.13%) participants. Non-proliferative SCR was present in 46 (47.92%) and proliferative SCR in 5 (5.21%) participants. OCT revealed vitreomacular traction, epiretinal membranes, and full-thickness macular holes. Patient age correlated with retinopathy severity (R² = 0.76, p < 0.01), and systemic severity correlated with retinopathy (R² = 0.94, p < 0.001). Conclusions SCD patients exhibit significant ocular manifestations, particularly retinal pathology, which correlates with age and systemic disease severity. Early and routine ophthalmologic screening is crucial for timely management and preventing vision loss.